Miles Wang, a prominent researcher from OpenAI, is reportedly in advanced discussions to establish a new startup focused on leveraging artificial intelligence for drug discovery. This venture, which could be valued at around $2 billion, is said to be in talks for funding led by Lightspeed Venture Partners. The initiative aims to combine cutting-edge AI technology with the pharmaceutical industry, potentially streamlining the drug development process and reducing costs significantly. As the healthcare sector increasingly embraces AI, this startup could position itself at the forefront of a transformative wave in drug discovery.
Source: TechCrunch
